Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Harrow Health to Participate in Two Upcoming Virtual Investor Conferences By: Harrow Health, Inc. via Business Wire August 12, 2021 at 07:45 AM EDT Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll, Chief Financial Officer, will participate in two upcoming virtual investor conferences. Harrow Health will participate in the H.C. Wainwright Ophthalmology Virtual Conference to be held August 17, 2021. The Company’s pre-recorded presentation will be available via a link on the investor relations section of its website, harrowinc.com, beginning at 7:00 a.m. ET on Tuesday, August 17, 2021, and will remain archived there for approximately 90 days. Harrow Health’s management team will be participating in one‑on-one meetings during the conference. Interested investors can request meetings exclusively via H.C. Wainwright. The Company will also be attending Lake Street Capital Market’s 5th Annual Best Ideas Growth Conference (BIG5) on September 15, 2021. Management will be available throughout the day for one-on-one meetings with investors to provide an update on the Company’s business. Investors should contact their Lake Street representative to arrange a meeting or request an invitation. About Harrow Health Harrow Health, Inc. (NASDAQ: HROW) is an ophthalmic-focused healthcare company. The Company owns and operates ImprimisRx, one of the nation’s leading ophthalmology-focused pharmaceutical businesses, and Visionology, a direct-to-consumer eye care subsidiary focused on chronic eye disease. Harrow Health also holds non-controlling equity positions in Eton Pharmaceuticals, Surface Ophthalmics and Melt Pharmaceuticals, all of which started as Harrow Health subsidiaries, and owns royalty rights in four clinical-stage drug candidates being developed by Surface Ophthalmics and Melt Pharmaceuticals. For more information about Harrow Health, please visit the Investors section of the corporate website, harrowinc.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20210812005137/en/Contacts Jamie Webb Director of Communications and Investor Relations jwebb@harrowinc.com 615-733-4737 Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Harrow Health to Participate in Two Upcoming Virtual Investor Conferences By: Harrow Health, Inc. via Business Wire August 12, 2021 at 07:45 AM EDT Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll, Chief Financial Officer, will participate in two upcoming virtual investor conferences. Harrow Health will participate in the H.C. Wainwright Ophthalmology Virtual Conference to be held August 17, 2021. The Company’s pre-recorded presentation will be available via a link on the investor relations section of its website, harrowinc.com, beginning at 7:00 a.m. ET on Tuesday, August 17, 2021, and will remain archived there for approximately 90 days. Harrow Health’s management team will be participating in one‑on-one meetings during the conference. Interested investors can request meetings exclusively via H.C. Wainwright. The Company will also be attending Lake Street Capital Market’s 5th Annual Best Ideas Growth Conference (BIG5) on September 15, 2021. Management will be available throughout the day for one-on-one meetings with investors to provide an update on the Company’s business. Investors should contact their Lake Street representative to arrange a meeting or request an invitation. About Harrow Health Harrow Health, Inc. (NASDAQ: HROW) is an ophthalmic-focused healthcare company. The Company owns and operates ImprimisRx, one of the nation’s leading ophthalmology-focused pharmaceutical businesses, and Visionology, a direct-to-consumer eye care subsidiary focused on chronic eye disease. Harrow Health also holds non-controlling equity positions in Eton Pharmaceuticals, Surface Ophthalmics and Melt Pharmaceuticals, all of which started as Harrow Health subsidiaries, and owns royalty rights in four clinical-stage drug candidates being developed by Surface Ophthalmics and Melt Pharmaceuticals. For more information about Harrow Health, please visit the Investors section of the corporate website, harrowinc.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20210812005137/en/Contacts Jamie Webb Director of Communications and Investor Relations jwebb@harrowinc.com 615-733-4737
Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll, Chief Financial Officer, will participate in two upcoming virtual investor conferences. Harrow Health will participate in the H.C. Wainwright Ophthalmology Virtual Conference to be held August 17, 2021. The Company’s pre-recorded presentation will be available via a link on the investor relations section of its website, harrowinc.com, beginning at 7:00 a.m. ET on Tuesday, August 17, 2021, and will remain archived there for approximately 90 days. Harrow Health’s management team will be participating in one‑on-one meetings during the conference. Interested investors can request meetings exclusively via H.C. Wainwright. The Company will also be attending Lake Street Capital Market’s 5th Annual Best Ideas Growth Conference (BIG5) on September 15, 2021. Management will be available throughout the day for one-on-one meetings with investors to provide an update on the Company’s business. Investors should contact their Lake Street representative to arrange a meeting or request an invitation. About Harrow Health Harrow Health, Inc. (NASDAQ: HROW) is an ophthalmic-focused healthcare company. The Company owns and operates ImprimisRx, one of the nation’s leading ophthalmology-focused pharmaceutical businesses, and Visionology, a direct-to-consumer eye care subsidiary focused on chronic eye disease. Harrow Health also holds non-controlling equity positions in Eton Pharmaceuticals, Surface Ophthalmics and Melt Pharmaceuticals, all of which started as Harrow Health subsidiaries, and owns royalty rights in four clinical-stage drug candidates being developed by Surface Ophthalmics and Melt Pharmaceuticals. For more information about Harrow Health, please visit the Investors section of the corporate website, harrowinc.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20210812005137/en/